NGM Biopharmaceuticals Investor Relations Material
Latest events
Study Result
NGM Biopharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from NGM Biopharmaceuticals Inc
Access all reports
NGM Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of liver and metabolic diseases, retinal diseases, and cancer. The company's key products in development include NGM707, a dual antagonist monoclonal antibody for advanced metastatic solid tumors, and Aldafermin, an engineered analog of a human hormone aimed at treating liver diseases such as non-alcoholic steatohepatitis. Additionally, NGM Biopharmaceuticals works on a variety of other drug candidates targeted at different therapeutic areas, using a biologics-based platform to create and evaluate monoclonal antibodies and other proteins. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
The Lego Story: Building a Business Brick by Brick
A detailed account of the most important milestones in the Lego Group's history, as well as an explanation of the philosophy guiding the company
2 May 2024
Kevin Plank and the Rise of Under Armour
Dive into the story of Under Armour and its founder Kevin Plank, highlighting both successes and mistakes.
30 Apr 2024
Ticker symbol
Country
🇺🇸 United States